Pancreatic Cancer Research

ResearcherAzienda Ospedaliero-Universitaria di ModenaActive in the last 2 years

Andrea Spallanzani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6955-7139; OpenAlex author ID A5026433226. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper

Papers 11

  1. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  2. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  3. Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. Co-author DOI 10.1016/j.xcrm.2024.101685↗
  4. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Co-author DOI 10.1093/bjsopen/zrad119↗
  5. Role of Body Composition in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.3390/nu16121834↗
  6. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  7. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  8. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomi… Co-author DOI 10.1016/j.ejca.2021.02.023↗
  9. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  10. Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. Last author DOI 10.3390/nu13103522↗
  11. TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. Co-author PMID 34659901↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingrid Garajová · 5 shared papers, 2021–2025 · strength 0.71
  2. Massimo Dominici · 4 shared papers, 2021–2024 · strength 0.60
  3. Marina Macchini · 4 shared papers, 2021–2025 · strength 0.55
  4. Mario Scartozzi · 4 shared papers, 2021–2025 · strength 0.55
  5. Giulia Orsi · 4 shared papers, 2021–2025 · strength 0.55
  6. Michele Reni · 4 shared papers, 2021–2025 · strength 0.55
  7. Alessandro Bittoni · 4 shared papers, 2021–2025 · strength 0.47
  8. Stefano Cascinu · 4 shared papers, 2021–2025 · strength 0.47
  9. Sara Lonardi · 3 shared papers, 2023–2025 · strength 0.46
  10. Umberto Peretti · 3 shared papers, 2021–2024 · strength 0.39
  11. Elisa Giommoni · 3 shared papers, 2021–2025 · strength 0.37
  12. Maria Grazia Rodriquenz · 3 shared papers, 2021–2025 · strength 0.37
  13. Mariacristina Di Marco · 3 shared papers, 2021–2025 · strength 0.37
  14. Silvia Bozzarelli · 3 shared papers, 2021–2025 · strength 0.37
  15. Guido Giordano · 3 shared papers, 2021–2025 · strength 0.37
  16. Ilario Giovanni Rapposelli · 3 shared papers, 2021–2025 · strength 0.37
  17. Monica Niger · 3 shared papers, 2021–2025 · strength 0.37
  18. Giampaolo Tortora · 3 shared papers, 2021–2025 · strength 0.37
  19. Michèle Milella · 3 shared papers, 2021–2025 · strength 0.37
  20. Stefania Mosconi · 3 shared papers, 2021–2025 · strength 0.35
  21. Renata Menozzi · 2 shared papers, 2021–2024 · strength 0.34
  22. Letizia Procaccio · 2 shared papers, 2023–2025 · strength 0.28
  23. Lisa Salvatore · 2 shared papers, 2023–2025 · strength 0.28
  24. Enrico Vasile · 2 shared papers, 2023–2025 · strength 0.28
  25. Carlotta Spano · 2 shared papers, 2021–2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.